Stephens Consulting’s Immunogen Inc IMGN Stock Holding History

Stephens Consulting’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-133	Closed	-$987	–	707
2021 Q4	$987	Buy	+133	New	+$827	﹤0.01%	659

Other funds holding IMGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stephens Consulting's IMGN Position: Q1 2022 in Review

Stephens Consulting sold out of Immunogen Inc (IMGN) in Q1 2022, closing a stake of 133 shares — an estimated $987 sold.

Stephens Consulting first reported a position in IMGN in Q4 2021 and held it in 1 quarter. The position peaked at $987 in Q4 2021. 217 funds tracked by Wall St. Rank hold IMGN as of Q1 2022.

Stephens Consulting reported no remaining Immunogen Inc position as of Q1 2022 after selling out during the quarter.
Stephens Consulting sold 133 Immunogen Inc shares in Q1 2022, an estimated $987.
Stephens Consulting first reported a position in Immunogen Inc in Q4 2021 and held it in 1 quarter.
Stephens Consulting's Immunogen Inc position peaked at $987 in Q4 2021.
217 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2022.

Based on Stephens Consulting's 13F filing for Q1 2022, filed 20 Jan 2023.